Laurus Labs stock gains 1.37 percent as profit jumps 126 percent

Laurus Labs stock gained 1.37 percent to INR 2,034 on the NSE on September 23, 2026, placing the price INR 3.20 below its 52-week high of INR 2,037.20. The move follows a sharp improvement in the latest quarterly earnings picture, with net profit up 126 percent year over year to INR 368 crore.

Revenue reaches INR 2,026 crore

For Q1 FY27, the quarter ended June 30, 2026, Laurus Labs reported revenue of INR 2,026 crore, up 29 percent from INR 1,570 crore in Q1 FY26. InvestyWise also reported EBITDA of INR 644 crore, a 66 percent year-over-year increase.

The earnings mix matters because profitability expanded faster than sales. EBITDA margin rose to 31.8 percent from 24.8 percent a year earlier, a 7.0 percentage-point improvement, while net margin reached 18.2 percent from 10.4 percent.

CDMO growth drives earnings

Contract development and manufacturing organization revenue increased 67 percent year over year to INR 870 crore in Q1 FY27, according to the latest market coverage. Affordable Medicines revenue rose 10 percent to INR 1,156 crore, adding a second growth channel to the quarterly result.

The comparison with Q1 FY26 is unusually wide: profit increased from INR 163 crore to INR 368 crore, while EBITDA advanced from INR 389 crore to INR 644 crore. That spread indicates that operating leverage and business mix contributed alongside higher revenue.

Stock stays near yearly high

Laurus Labs stock stood at INR 2,034 on the NSE on September 23, 2026, with a 52-week range of INR 823.10 to INR 2,037.20. The share price was therefore 0.16 percent below the yearly high, while the market capitalization stood at INR 1,098,868,500,000.

Laurus Labs also scheduled an analyst and investor interaction for September 22, 2026, as reported by Sahi. For investors, the next material test is whether the Q1 margin profile can remain aligned with the companys accelerated growth investment.